U.S. markets closed
  • S&P 500

    4,063.04
    -89.06 (-2.14%)
     
  • Dow 30

    33,587.66
    -681.50 (-1.99%)
     
  • Nasdaq

    13,031.68
    -357.75 (-2.67%)
     
  • Russell 2000

    2,135.14
    -71.85 (-3.26%)
     
  • Crude Oil

    65.74
    +0.46 (+0.70%)
     
  • Gold

    1,814.40
    -21.70 (-1.18%)
     
  • Silver

    27.08
    -0.59 (-2.14%)
     
  • EUR/USD

    1.2080
    -0.0072 (-0.59%)
     
  • 10-Yr Bond

    1.6950
    +0.0710 (+4.37%)
     
  • GBP/USD

    1.4049
    -0.0095 (-0.67%)
     
  • USD/JPY

    109.6310
    +1.0110 (+0.93%)
     
  • BTC-USD

    54,397.36
    -2,453.36 (-4.32%)
     
  • CMC Crypto 200

    1,470.93
    -92.90 (-5.94%)
     
  • FTSE 100

    7,004.63
    +56.64 (+0.82%)
     
  • Nikkei 225

    28,147.51
    -461.08 (-1.61%)
     

Assembly Bio/Arbutus Bio Start Testing Vebicorvir/AB-729 Triplet Therapy In HBV Infection

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Assembly Biosciences Inc (NASDAQ: ASMB) and Arbutus Biopharma Corp (NASDAQ: ABUSinitiated a Phase 2 trial evaluating the former's vebicorvir (VBR), combined with the latter's AB-729 and standard-of-care nucleos(t)ide reverse transcriptase inhibitor (NrtI) therapy for chronic HBV infection.

  • The companies announced a clinical collaboration agreement in August last year.

  • The 60-subject trial will evaluate the safety, pharmacokinetics, and antiviral activity of the triplet combination compared to the double combinations of VBR plus NrtI and AB-729 plus NrtI.

  • AB-729 is an RNA interference therapeutic targeted to hepatocytes. 

  • Vebicorvir is a capsid inhibitor.

  • Earlier today, Assembly Biosciences announced that it would not initiate Phase 3 studies of vebicorvir (VBR, or ABI-H0731) as chronic suppressive therapy.

  • Price Action: ASMB shares are trading 5.9% lower at $5.2, while ABUS is down 0.8% at $3.8 in market trading hours on the last check Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.